Burning Rock Biotech Limited (BNR)

Market Cap	137.52M +4.7%
Revenue (ttm)	73.70M -6.7%
Net Income	-10.01M
EPS	-0.95
Shares Out	10.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,393
Open	13.06
Previous Close	13.42
Day's Range	13.04 - 13.06
52-Week Range	6.79 - 41.72
Beta	1.52
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 23, 2026

About BNR

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cance...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 667
• Stock Exchange: Nasdaq
• Ticker Symbol: BNR
• Website: https://www.brbiotech.com

Financial Performance

In 2025, Burning Rock Biotech's revenue was 539.57 million, an increase of 4.60% compared to the previous year's 515.82 million. Losses were -55.35 million, -84.03% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 9, 2026

Data Sources Report a data error